This site uses cookies and by using the site you are consenting to this. Find out what cookies are, why we use them and how to manage your settings in our cookie policy.

Changing your cookie settings

All browsers provide tools that allow you to control how they handle cookies: accept, reject or delete them. These settings are normally accessed via the 'preferences' or 'options' menu of the browser you are using. Read more...

C4X Discovery

Better, Safer, Faster

Non-Executive Director: Alex Stevenson, PhD

Alex has a proven track record in identifying, investing and growing business within the pharmaceutical sector. He began his career as a scientist, working in research and for a NYSE quoted drug development company, before moving into early stage pharmaceutical and healthcare investments. He has fulfilled board level investment and operational management roles. He is Chief Scientific Officer at 4d pharma plc.

From 2008, he was a director and shareholder in Aquarius Equity Partners Limited. Aquarius Equity Partners Limited invested in C4XD in 2008, when Alex joined the board as a non-executive director. Prior to joining Aquarius Equity Partners Limited, Alex worked for IP Group plc where he specialised in life science investments, identifying, developing and advising a number of companies in its portfolio, some of which went on to list on AIM.

Alex has been involved in a number of private and public companies, including Nanoco Group plc, admitted to AIM in 2009; Retroscreen Virology Group plc admitted to AIM in 2012; Tissue Regenix Group plc admitted to AIM in 2010; Auralis Limited, which, after investment through Aquarius Equity Partners Limited, delivered a 7 fold return through to its trade sale to ViroPharma Inc in 2010; 4d pharma plc, admitted to AIM in 2014.

Copyright © 2016 C4X Discovery Holdings plc.
Registered in England and Wales with registered number 09134041.
Registered office: Manchester One, 53 Portland Street, Manchester M1 3LD, United Kingdom.

Medilink Business Awards 2013 - Innovation